Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 30Breast Neoplasms 29Glioblastoma 23Multiple Myeloma 21Glioma 20Lymphoma 19Pancreatic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 16Brain Neoplasms 14Sarcoma 13Squamous Cell Carcinoma of Head and Neck 12Rectal Neoplasms 11Neoplasm Metastasis 11Melanoma 11Lymphoma, Non-Hodgkin 11Thyroid Neoplasms 10Ovarian Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 9Mouth Neoplasms 9Medulloblastoma 9Lymphoma, Follicular 9Ependymoma 9Colorectal Neoplasms 9Central Nervous System Neoplasms 9Astrocytoma 9

Interventions

Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligometastatic Prostate Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡